All News

Pricing, safety, comparative effectiveness, patents, and biosimilars top 2008's policy agenda

Pharma defends itself against claims made in charity's report on drug access for the world's poor

A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?

Economist Conference, Pharma 2020

When it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers

Pharma companies would do well to proceed with extreme caution when entering the blogosphere

GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion.

Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media.

Avandia is not getting pulled from the market, but that doesn't mean prescription benefit managers are going to take any chances with the controversial diabetes med. Two PBMs have already stated that they will be dropping the drug from their formularies.

European Sales Manager

The State of Arkansas filed suit against Risperdal manufacturer Johnson & Johnson, claiming promotion of the drug for nonmedical uses has led to increased prescriptions being written and bigger payouts by Medicaid.

The European CRO industry is becoming more competitive and complex by the day. What will it take to remain successful in this rapidly evolving landscape? Alan Morgan investigates.

Science is the lifeblood of pharma, of course. But these days, science isn't just what you produce in your own labs. It's what you can license, buy, partner on, or gain through acquisition. Which means that, increasingly, deals are the lifeblood of pharma.

One of industry's main complaints is that delaying the introduction of new medicines is a particularly simple way of saving money

In August, eMarketer reported that Internet ad sales had officially displaced radio ad sales, nabbing the slot of fourth-largest ad medium. That was a huge blow to radio, which receives a sizable chunk of ad dollars from the pharma industry. Now pharma marketers have a new option-ReachMD, a 24-hour satellite radio station that plays content targeted at doctors.

The ultimate goal is for the medical system to develop new evidence as a natural by-product of delivering appropriate care

The proof is in the metrics. Last June, MarkMonitor sifted through 60 million e-mail messages and billions of Web pages to get a handle on how six major brand-name drugs were being touted and sold on the Internet. In the process, it found nearly 3,200 online pharmacies selling those drugs, according to the Summer 2007 MarkMonitorBrandjacking Index. But only four-count 'em-of these e-stores carried the respected Verified Internet Pharmacy Practice Site (VIPPS) accreditation.

It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings-and magazines make up their lists of hits and has-beens.

For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?

A crush of Phase III failures triggered an R&D turnaround at AstraZeneca

Event closed

TKTKTKTKTKTK

A physician-oriented search engine reveals its most-searched terms. Among the winners: breast and lung cancer, cortisol, and HbA1c/glycated hemoglobin. Nowhere to be seen: pharmaceutical products.

Cambridge Major Laboratories has acquired ChemShop BV, a supplier of API development services, and plans to invest millions of dollars to expand the company's facilities.

Cavidi AB has signed an agreement with a consortium of American and Swedish investors, raising over $1.0 million to drive forward Cavidi's newly adopted three-year business plan.

A new pharma-sponsored documentary chronicles one doctor?s adventure around the world as she searches for stories about living with diabetes. The program, sponsored by Novo Nordisk, enlightens viewers and offers physicians a chance to earn one AMA-approved CME credit.

Abbott Laboratories has received a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis.